top of page


Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement
Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases.

nuaxia
1 day ago2 min read


FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer
Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.

nuaxia
1 day ago2 min read


Lupin and Sandoz launch Ranluspec ranibizumab biosimilar across Europe following EC approval
Lupin and commercial partner Sandoz have begun launching Ranluspec, a ranibizumab biosimilar, across European markets excluding Germany, expanding commercial competition in treatments for retinal vascular diseases.

nuaxia
4 days ago2 min read


China approves Bio-Thera's Ashuli as its first golimumab biosimilar
Bio-Thera has secured Chinese regulatory approval for Ashuli, the country's first golimumab biosimilar, expanding domestic biosimilar competition in rheumatoid arthritis and ankylosing spondylitis.

nuaxia
Nov 102 min read


Teva secures US commercialisation rights to two Samsung Bioepis immunology biosimilars in deal worth up to $420 million
Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio.

nuaxia
Nov 42 min read


Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates
Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.

nuaxia
Nov 32 min read


FDA approves STADA and Xbrane Lucamzi ranibizumab biosimilar for retinal diseases
The FDA has approved Lucamzi, a ranibizumab biosimilar developed by Xbrane Biopharma and commercialised through STADA, expanding treatment competition in retinal diseases.

nuaxia
Oct 302 min read


Adalvo acquires Enzene romiplostim biosimilar programme targeting global Nplate market
Adalvo has acquired Enzene's romiplostim biosimilar programme, expanding its complex biologics portfolio with a candidate referencing Nplate for immune thrombocytopenia.

nuaxia
Oct 282 min read


Biocon expands Yesintek biosimilar licensing rights to nine additional international markets
Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint.

nuaxia
Oct 272 min read


China approves Bio-Thera BAT2306 as world's first secukinumab biosimilar
China has approved Bio-Thera's BAT2306 as the first secukinumab biosimilar authorised by a major regulator worldwide, opening a new biosimilar competition category.

nuaxia
Oct 272 min read


Biocon secures 10-year pertuzumab supply partnership in Brazil
Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme.

nuaxia
Sep 101 min read
bottom of page